Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

Science Spotlight: Using HIV to help allogeneic CAR T cells evade immune attack

BioCentury’s roundup of translational innovations also includes a human hypothalamus atlas from Novo and collaborators, and four papers with links to newcos

February 15, 2025 1:29 AM UTC

A group led by Michel Sadelain at Memorial Sloan Kettering Cancer Center devised a method to reduce immune rejection of allogeneic CAR T cells, borrowing from a mechanism that viruses use to evade the immune system. The modification could help allogeneic cells overcome their durability limitations in vivo.

CAR T cells with full human leukocyte antigen I (HLA-I) activity are rejected by host CD8+ T cells and NK cells. Eliminating HLA-I activity can avoid T cell recognition, but the cells are still susceptible to rejection by NK cells, which target cells missing HLA-I. The authors of the Nature paper showed that adding the HIV-1 viral immune evasion protein Nef to CAR T cells reduced HLA-I levels to a “happy medium,” leading to partial protection from CD8+ T cell killing without triggering NK cells...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article